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Perspective

The term “bioequivalence” refers to pharmaceutically equivalent
products where the extent of bioavailability of the actives are not
significantly (in the statistical sense) different under scientific
conditions usually following the rules of scientific sampling. As a student
of the famous W.E. Deming (1900-1993) these words are common
knowledge to people and researchers like me. To those not attuned
to scientific sampling, these methods and the term bioequivalence
would have no meaning. With strong backing by agencies involved in
the testing of new pharmaceuticals and retesting of established drugs
(both generic and proprietary) created by “perfect” law, the results
will always be sound and scientifically justifiable.
In the United States, agencies of government are working
to keep the creation of new pharmaceuticals safe and useful in
both the diagnosis and treatment of a huge number of health
treatment and diagnostic problems. In the common sense of the
term bioequivalence, society would feel confident that two or more
pharmaceuticals are equivalent if their characteristics and purpose
of curing the same treatment or diagnosis in the very same manner.
Two or more pharmaceuticals if examined scientifically may show
results that cannot be found statistically different. If that occurs the
two or more drugs would be bioequivalent. Perfect law would have
the purpose of establishing the scientific system for such a process.
Those who dispute this have several arguments. Law may not be
“perfect” and imperfect law creates conflict in the interpretation of
the law and its eventual execution. We live in a society where law
governs and to which we call “living law.” Hence, science advances the
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development and creates bioequivalent pharmaceuticals. Also, creates
and develops testing methods employed by agencies of government
to produce safety in usage and effects of pharmaceuticals and also
in the use bioequivalent products. Last, using phrases like increase
bioequivalence makes no sense from a sampling and testing point of
view. Borrowing from previous scientific work, we can if two products
are equivalent in every manner they cannot be different in anyway.
If sampling differences are found, then we must determine if the
difference is sufficiently large as to conclude that sampling variation
cannot explain the small differences in the samples observed and
analyzed. Monitoring results of tests is important to make certain that
two products that found to be different come from separate and not
equal populations.
Bioavailability refers to the extent to which a pharmaceutical
reaches its site of action or a biological fluid such as blood that can access
to its site of action. The two terms bioequivalence and bioavailability
do not mean the same. Bioavailability is a subcategory of absorption
and is the percentage of an administered dose of a product or drug that
reaches circulation. This is a property of a drug and is part of principal
pharma kinetic characteristics of pharmaceuticals. By definition,
when a medication is administered intravenously, its bioavailability
is 100%. Hence bioavailability and bio equivalence have different
meaning and one can speak in terms of percentages of bioavailability
but one cannot speak in terms percentages of bioequivalence. These
are important concepts to understand whenever one analyzes large
data sets sampled from populations.
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